These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35142337)

  • 1. Genital Immune Cell Activation and Tenofovir Gel Efficacy: A Case-Control Study.
    Liebenberg LJP; Passmore JAS; Osman F; Jewanraj J; Mtshali A; Garcia-Lerma JG; Heneine W; Holder A; Archary D; Ngcapu S; Sivro A; Mansoor LE; Abdool Karim Q; Abdool Karim SS; McKinnon LR
    Clin Infect Dis; 2022 Sep; 75(6):1088-1091. PubMed ID: 35142337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.
    Cottrell ML; Yang KH; Prince HM; Sykes C; White N; Malone S; Dellon ES; Madanick RD; Shaheen NJ; Hudgens MG; Wulff J; Patterson KB; Nelson JA; Kashuba AD
    J Infect Dis; 2016 Jul; 214(1):55-64. PubMed ID: 26917574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion.
    Lee SS; Anderson PL; Kwan TH; Lui GCY; Chan DPC; Wong NS; Lee KCK; Lam TTN
    Int J Infect Dis; 2020 May; 94():41-43. PubMed ID: 32173577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexposure Prophylaxis.
    Nicol MR; Eneh P; Nakalega R; Kaiser T; Kabwigu S; Isingel E; Beksinska M; Sykes C; Fowler MG; Brown TT; Staley C; Kiweewa Matovu F
    Clin Infect Dis; 2020 Apr; 70(8):1717-1724. PubMed ID: 31131846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.
    Hoagland B; Moreira RI; De Boni RB; Kallas EG; Madruga JV; Vasconcelos R; Goulart S; Torres TS; Marins LMS; Anderson PL; Luz PM; Costa Leite ID; Liu AY; Veloso VG; Grinsztejn B;
    J Int AIDS Soc; 2017 Apr; 20(1):21472. PubMed ID: 28418232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
    Krakower DS; Mayer KH
    Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
    Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection.
    Stalter RM; Baeten JM; Donnell D; Spinelli MA; Glidden DV; Rodrigues WC; Wang G; Vincent M; Mugo N; Mujugira A; Marzinke M; Hendrix C; Gandhi M;
    Clin Infect Dis; 2021 Feb; 72(3):486-489. PubMed ID: 33527128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study.
    Mboup A; Béhanzin L; Guédou FA; Geraldo N; Goma-Matsétsé E; Giguère K; Aza-Gnandji M; Kessou L; Diallo M; Kêkê RK; Bachabi M; Dramane K; Geidelberg L; Cianci F; Lafrance C; Affolabi D; Diabaté S; Gagnon MP; Zannou DM; Gangbo F; Boily MC; Vickerman P; Alary M
    J Int AIDS Soc; 2018 Nov; 21(11):e25208. PubMed ID: 31291057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy.
    Cirrincione LR; Podany AT; Havens JP; Bares SH; Dyavar SR; Gwon Y; Johnson TM; Amoura NJ; Fletcher CV; Scarsi KK
    J Antimicrob Chemother; 2020 May; 75(5):1242-1249. PubMed ID: 32065631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
    Glidden DV; Das M; Dunn DT; Ebrahimi R; Zhao Y; Stirrup OT; Baeten JM; Anderson PL
    J Int AIDS Soc; 2021 May; 24(5):e25744. PubMed ID: 34021709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention.
    Nicol MR; Corbino JA; Cottrell ML
    J Clin Pharmacol; 2018 Nov; 58(11):1381-1395. PubMed ID: 29901863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
    Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
    Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention.
    Yap PK; Loo Xin GL; Tan YY; Chellian J; Gupta G; Liew YK; Collet T; Dua K; Chellappan DK
    J Pharm Pharmacol; 2019 Sep; 71(9):1339-1352. PubMed ID: 31144296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis.
    Abdool Karim SS; Baxter C; Abdool Karim Q
    Antivir Ther; 2022 Apr; 27(2):13596535211067589. PubMed ID: 35499171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV Preexposure Prophylaxis: A Review.
    Riddell J; Amico KR; Mayer KH
    JAMA; 2018 Mar; 319(12):1261-1268. PubMed ID: 29584848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis.
    Srinivas N; Cottrell M; Maffuid K; Prince HA; Nelson JAE; White N; Sykes C; Dellon ES; Madanick RD; Shaheen NJ; Gonzalez D; Kashuba ADM
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31740561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?
    Taramasso L; Riccardi N; Del Puente F; Bruzzone B; Ripamonti D; D'Ambrosio B; Viscoli C; Di Biagio A
    AIDS Res Hum Retroviruses; 2018 Feb; 34(2):168-170. PubMed ID: 29166777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
    Özdener AE; Park TE; Kalabalik J; Gupta R
    Expert Rev Anti Infect Ther; 2017 May; 15(5):467-481. PubMed ID: 28322067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unsupervised PrEP in routine practice: a new challenge?
    Laroche H; Lions C; Zaegel-Faucher O; Tamalet C; Poizot-Martin I
    Int J STD AIDS; 2019 Jun; 30(7):715-717. PubMed ID: 30975069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.